Semaglutide, a medication initially developed to treat Type 2 Diabetes, has shown promising results in weight loss studies
While the Phase 2 trial did not specifically stratify outcomes by baseline eGFR, GLP-1 receptor agonists as a class have demonstrated renoprotective effects in at-risk populations
When cagrilintide activates those receptors, a few things happen: Your brain gets stronger fullness signals after eating, which may help you feel satisfied with less food
Total marker baseline Comprehensive bloodwork and advanced assessments covering hormones, metabolic markers, inflammation, nutrition, and longevity-specific indicators that standard labs simply don't run
There are also reports of seasonal variation in thyroid function
As research continues to evolve, AOD-9604 may emerge as a valuable tool in the expanding field of regenerative medicine for joint conditions